Despite their large size, antibodies (Abs) are suitable carriers to deliver systemic radiotherapy, often molecular image-based, for lymphoma and leukemia. Lym-1 Ab has proven to be an effective radioisotope carrier, even in small amounts, for targeting human leukocyte antigen DR (HLA-DR), a surface membrane protein overexpressed on B-cell lymphoma. Pairs of molecules (referred to as ligands), shown by computational and experimental methods to bind to each of 2 sites within the Lym-1 epitopic region, have been linked to generate small (kDa) molecules (referred to as selective high-affinity ligands [SHALs]) to mimic the targeting properties of Lym-1 Ab. Methods: A lysine-polyethylene glycol (PEG) backbone was used to synthetically link 2 of t...
Prolonged clearance kinetics have hampered the development of intact antibodies as imaging agents, d...
The pharmacokinetics of a humanized anti-RNLS monoclonal antibody used for the treatment of melanoma...
B7-H3 (CD276), an immune checkpoint protein, is a promising molecular target for immune therapy of m...
Despite their large size, antibodies have proven to be suitable radioisotope carriers to deliver sys...
Radioimmunotherapy (RIT) is a new and effective treatment modality in patients with non-Hodgkin's ly...
New lymphatic imaging technologies are needed to better assess immune function and cancer progressio...
It is known that major histocompatibility complex class II protein HLA-DR is highly expressed in B-c...
It is known that major histocompatibility complex class II protein HLA-DR is highly expressed in B-c...
BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
Background: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
In the last grant period we have focused on multi-step targeting methodologies (MST), as a method fo...
Radioimmunotherapy (RIT) has emerged as a new form of effective treatment for this disease. In this...
Tumor-associated peptide–human leukocyte antigen complexes (pHLAs) represent the largest pool of cel...
A major challenge in developing new cancer therapies is specifically killing cancer cells without ha...
B lymphocyte stimulator (BLyS) protein is a member of the tumor necrosis factor (TNF) superfamily of...
Prolonged clearance kinetics have hampered the development of intact antibodies as imaging agents, d...
The pharmacokinetics of a humanized anti-RNLS monoclonal antibody used for the treatment of melanoma...
B7-H3 (CD276), an immune checkpoint protein, is a promising molecular target for immune therapy of m...
Despite their large size, antibodies have proven to be suitable radioisotope carriers to deliver sys...
Radioimmunotherapy (RIT) is a new and effective treatment modality in patients with non-Hodgkin's ly...
New lymphatic imaging technologies are needed to better assess immune function and cancer progressio...
It is known that major histocompatibility complex class II protein HLA-DR is highly expressed in B-c...
It is known that major histocompatibility complex class II protein HLA-DR is highly expressed in B-c...
BACKGROUND: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
Background: The delivery of antibody-targeted major histocompatibility complex (MHC) class I complex...
In the last grant period we have focused on multi-step targeting methodologies (MST), as a method fo...
Radioimmunotherapy (RIT) has emerged as a new form of effective treatment for this disease. In this...
Tumor-associated peptide–human leukocyte antigen complexes (pHLAs) represent the largest pool of cel...
A major challenge in developing new cancer therapies is specifically killing cancer cells without ha...
B lymphocyte stimulator (BLyS) protein is a member of the tumor necrosis factor (TNF) superfamily of...
Prolonged clearance kinetics have hampered the development of intact antibodies as imaging agents, d...
The pharmacokinetics of a humanized anti-RNLS monoclonal antibody used for the treatment of melanoma...
B7-H3 (CD276), an immune checkpoint protein, is a promising molecular target for immune therapy of m...